Johnson & Johnson boosted its research efforts into battling Alzheimer's on Monday, striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.Tau is a protein known for forming twisted fibres inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.The hope is that therapeutic vaccines targeting tau will offer a way to treat Alzheimer's patients early in the disease.It is a decade since the last drug was approved for Alzheimer's, and there is still no treatment that can slow its progression, with current drugs only easing some of its symptoms.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ traded higher by 0.26% or $0.27/share to $105.21. In the past year, the shares have traded as low as $86.09 and as high as $109.49. On average, 8268920 shares of JNJ exchange hands on a given day and today's volume is recorded at 2581869.
Source
